GENOR BIOPHARMA DL-00002 (67N0) — Net Asset Momentum
GENOR BIOPHARMA DL-00002 (67N0) recorded a net asset momentum of -3.3% as of December 2024, with net assets of €1.15 Billion EUR. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Check 67N0 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
YoY Momentum
Current Net Assets
Years of Data
Country
GENOR BIOPHARMA DL-00002 Net Asset Momentum (2021–2024)
This chart tracks GENOR BIOPHARMA DL-00002's year-over-year net asset growth across 4 annual reporting periods from 2021 to 2024. The most recent momentum reading is -3.3%, with net assets of €1.15 Billion EUR as of December 2024. Read 67N0 total debt and obligations for a breakdown of total debt and financial obligations.
Annual Net Asset History for GENOR BIOPHARMA DL-00002 (2021–2024)
The table below shows the complete annual net asset history for GENOR BIOPHARMA DL-00002 from 2021 to 2024, covering 4 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see GENOR BIOPHARMA DL-00002 (67N0) market capitalisation.
| Year | Net Assets (EUR) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2024 | €1.15 Billion | €1.29 Billion | €138.05 Million | ▼ -3.3% |
| 2023 | €1.19 Billion | €1.45 Billion | €256.18 Million | ▼ -34.0% |
| 2022 | €1.81 Billion | €2.12 Billion | €309.87 Million | ▼ -27.6% |
| 2021 | €2.49 Billion | €2.86 Billion | €369.73 Million | — |